Yüklüyor......
Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation
BACKGOUND: The mechanistic target of rapamycin complex 1 (mTORC1) is important in the development and progression of many cancers. Targeted cancer therapy using mTORC1 inhibitors is used for treatment of cancers; however, their clinical efficacies are still limited. METHODS: We recently created a ne...
Kaydedildi:
| Yayımlandı: | Br J Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7283252/ https://ncbi.nlm.nih.gov/pubmed/32336756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0839-1 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|